LDV/SOF FDC

ApprovedSmall molecule

HHepNet Study House, German Liverfoundation

LDV/SOF FDC is one of 84 small molecule programs targeting Autoimmune Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Hepatitis C Virus InfectionActive, not recruiting

Autoimmune DiseaseApproved

Active, not recruiting

Hepatitis C Virus InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 3

1 2

Remicade

OOrganon and Co

Phase 3

2 3

Atgam

Novartis

Phase 2

2 4

Blincyto

Amgen

Phase 2

1 5

Cytosar

Teva

Phase 2

1 6

Soliris

Rayos

2 8

LDV/SOF FDC

HHepNet Study House, German Liverfoundation

Approved

1 9

Alkeran

AApotex Inc.

Phase 2

1 10

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

Unknown status·PPeter J. Ruane, M.D., Inc.·Phase 4·NCT02691728·40 enrolled

Hepatitis C Virus Infection1 trial

HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection

Completed·HHepNet Study House, German Liverfoundation·Phase 2·NCT02309918·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LDV/SOF FDC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LDV/SOF FDC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LDV/SOF FDC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HepNet Study House, German Liverfoundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHepNet Study House, German Liverfoundation

LDV/SOF FDC

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autoimmune Disease1 trial

Hepatitis C Virus Infection1 trial

References

Drug Info

Quick Facts

Related News